RXST Quote, Financials, Valuation and Earnings

PROCEPT BioRobotics has a net margin of -17.95% compared to RxSight's net margin of -35.93%. RxSight's return on equity of -14.78% beat PROCEPT BioRobotics's return on equity of -37.42%.

RxSight has a consensus price target of $58.00, signalling upside risk potential of 72.26%. On the other hand PROCEPT BioRobotics has an analysts' consensus of $102.75 which suggests that it could grow by 26.59%. Given that RxSight has higher upside potential than PROCEPT BioRobotics, analysts believe RxSight is more attractive than PROCEPT BioRobotics.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PROCEPT BioRobotics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. PROCEPT BioRobotics pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $35.3M, which are smaller than PROCEPT BioRobotics quarterly revenues of $58.4M. RxSight's net income of -$6.3M is higher than PROCEPT BioRobotics's net income of -$21M. Notably, RxSight's price-to-earnings ratio is -- while PROCEPT BioRobotics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 9.91x versus 20.84x for PROCEPT BioRobotics. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -17.95% compared to RxSight's net margin of -18.58%. RxSight's return on equity of -14.78% beat Retractable Technologies's return on equity of -16.83%.

RxSight has a consensus price target of $58.00, signalling upside risk potential of 72.26%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that RxSight has higher upside potential than Retractable Technologies, analysts believe RxSight is more attractive than Retractable Technologies.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

RxSight quarterly revenues are $35.3M, which are larger than Retractable Technologies quarterly revenues of $10.3M. RxSight's net income of -$6.3M is lower than Retractable Technologies's net income of -$1.9M. Notably, RxSight's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 9.91x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -17.95% compared to RxSight's net margin of -4291.67%. RxSight's return on equity of -14.78% beat Catheter Precision's return on equity of -65.84%.

RxSight has a consensus price target of $58.00, signalling upside risk potential of 72.26%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 506.06%. Given that Catheter Precision has higher upside potential than RxSight, analysts believe Catheter Precision is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $35.3M, which are larger than Catheter Precision quarterly revenues of $96K. RxSight's net income of -$6.3M is lower than Catheter Precision's net income of -$4.1M. Notably, RxSight's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 9.91x versus 0.88x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -17.95% compared to RxSight's net margin of -17.98%. RxSight's return on equity of -14.78% beat Xtant Medical Holdings's return on equity of -35.98%.

RxSight has a consensus price target of $58.00, signalling upside risk potential of 72.26%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Xtant Medical Holdings has higher upside potential than RxSight, analysts believe Xtant Medical Holdings is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $35.3M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. RxSight's net income of -$6.3M is lower than Xtant Medical Holdings's net income of -$5M. Notably, RxSight's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 9.91x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.